Pulmonx Stock

Pulmonx FCF Yield

The Free Cash Flow Yield of Pulmonx (LUNG) as of Aug 11, 2026 is -56.04 %. In the previous year, Free Cash Flow Yield was -56.18 % — a change of -0.26% (higher).

FCF Yield

-56.04 %

YoY

-0.26%

Last updated:

Free Cash Flow Yield of Pulmonx is 2026 -56.04 % . Free Cash Flow Yield of Pulmonx was 2025 -56.18 % . It decreases by -0.26% higher compared to the previous year.
Access this data via the Eulerpool API

Pulmonx Stock analysis

What does Pulmonx do? Pulmonx Corp is an innovative medical technology company based in the USA and Europe. The company specializes in the development of non-invasive solutions for the treatment of lung diseases. Pulmonx was founded in 1997 and has since introduced numerous groundbreaking technologies to the market that improve the quality of life for patients with chronic lung diseases. Pulmonx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulmonx stock

Free Cash Flow Yield of Pulmonx is -56.04 % in 2026.

Free Cash Flow Yield of Pulmonx changed from -56.18 % to -56.04 %, representing a -0.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Pulmonx since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Pulmonx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Pulmonx

All Key Metrics — Pulmonx